Compare FDP & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FDP | PGEN |
|---|---|---|
| Founded | 1886 | 1998 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1999 | 2013 |
| Metric | FDP | PGEN |
|---|---|---|
| Price | $29.35 | $3.86 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 523.9K | ★ 4.6M |
| Earning Date | 05-05-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.21 | N/A |
| Revenue | ★ $4,322,300,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $3.14 | $81.04 |
| P/E Ratio | $136.00 | ★ N/A |
| Revenue Growth | ★ 0.98 | N/A |
| 52 Week Low | $28.13 | $1.38 |
| 52 Week High | $43.58 | $5.47 |
| Indicator | FDP | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 26.54 | 44.47 |
| Support Level | N/A | $3.49 |
| Resistance Level | $38.19 | $4.40 |
| Average True Range (ATR) | 1.09 | 0.24 |
| MACD | -0.08 | -0.07 |
| Stochastic Oscillator | 17.97 | 27.79 |
Fresh Del Monte Produce Inc is an integrated producer, marketer & distributor of fresh-cut fruit & vegetables. It operates in three segments, Fresh and value-added products segment, which includes pineapples, fresh-cut fruit, fresh-cut vegetables, melons, vegetables, non-tropical fruit, other fruit and vegetables, avocados, and prepared foods, Banana segment & Other products and services segment, including the third-party freight & logistic services business & the Jordanian poultry and meats business. The majority is from the Fresh and value-added products segment. Geographically, it operates in North America, Europe, Asia, the Middle East, and Other, out of which the highest is from North America.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.